

Confirmed Speakers

Confirmed Speakers

Metal-Catalyzed C–H Bond Functionalizations for Sustainable Synthesis

Prof. Lutz ACKERMANN
(GEORG-AUGUST UNIVERSITY GOETTINGEN, Goettingen, Germany)

Chemical Probes for Epigenetics

Dr Mark BUNNAGE
(PFIZER, Boston, United States)

Novel Metabotropic Glutamate Receptor 4 (mGluR4) Allosteric Potentiators for the Treatment of Parkinson's Disease

Dr Sylvain CELANIRE
(ADDEX PHARMACEUTICALS, Geneva, Switzerland)

A few of my Favorite Rings: Catalysis Inspired by Lactones and Lactams

Prof. Vy M. DONG
(UNIVERSITY OF TORONTO, Toronto, Canada)

Tofacitinib (CP-690,550): Discovery of a Potent and Selective JAK Inhibitor

Dr Mark FLANAGAN
(PFIZER, Connecticut, United States)

Antibody Directed Cytotoxics

Prof. John FLYGARE
(GENENTECH, California, United States)

From Homer to Hedgehog: Chemistry, Biological Investigations and Medical Perspectives of Cyclopamine

Prof. Athanassios GIANNIS
(UNIVERSITY OF LEIPZIG, Leipzig, Germany)

Bicyclic Peptides with Tailored Binding Specificities for Therapeutic Application

Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Regioselective Reactions on a Chiral Substrate Controlled by the Configuration of a Chiral Catalyst

Prof. Henri KAGAN
(UNIVERSITY PARIS-SUD 11, ORSAY Cedex, France)

Discovery and Development of Novel Antimalarials

Dr Rodney KIP GUY
(ST. JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States)

Target Synthesis Directed Methodology Development

Prof. Dawei MA
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China)

Minor Enantiomer Recycling – A Strategy for Improving Enantioselectivity

Prof. Christina MOBERG
(KTH SCHOOL OF CHEMICAL SCIENCE AND ENGINEERING, Stockholm, Sweden)

Magical Power of d-Block Transition Metals—Pd-Catalyzed Cross-Coupling and Zr-Catalyzed Asymmetric carboalumination of Alkenes (ZACA)

Prof. Ei-ichi NEGISHI
(PURDUE UNIVERSITY, West Lafayette, United States)

Maitotoxin. An Inspiration for Synthesis

Confirmed Speakers

Prof. K.C. NICOLAOU
(THE SCRIPPS RESEARCH INSTITUTE & UNIVERSITY OF CALIFORNIA, Houston, United States)

Small Molecules Inhibitors of the WNT Signalling Pathway with Potential Applications in Oncology

Dr Alessandro PADOVA
(SIENA BIOTECH, Siena, Italy)

Design Strategy for Preparation of Drug-like Polyheterocycles with Privileged Substructures for Discovery of Specific Small Molecule Modulators

Prof. Seung Bum PARK
(SEOUL NATIONAL UNIVERSITY, Seoul, Korea, South)

Synthesis of Marine Polyketides as Promising Anticancer Agents

Prof. Ian PATERSON
(CAMBRIDGE UNIVERSITY, Cambridge, United Kingdom)

GPR119: Knowledge Based Lead Identification

Dr Sherrie L. PIETRANICO-COLE
(ROCHE, NUTLEY NJ, United States)

A Step Closer to Hepatitis C Remedy: TMC435, an HCV Protease Inhibitor in Advanced Clinical Trial

Dr Pierre RABOISSON
(JANSSEN PHARMACEUTICAL COMPANIES, Mechelen, Belgium)

The Many Uses of Noncovalent Mass Spectrometry in Early-stage Drug Discovery

Dr Jean-Paul RENAUD
(NOVALIX, Ostwald, France)

The Resurgence of Covalent Drugs

Dr Juswinder SINGH
(AVILA THERAPEUTICS, United States)

Lessons in Chemoselectivity: Total Synthesis of Polyphenolic Natural Products

Prof. Scott SNYDER
(COLUMBIA UNIVERSITY, New York, United States)

Asymmetric Synthesis of Bioactive Molecules

Prof. Mikiko SODEOKA
(RIKEN, Hirosawa, Japan)

Biochemical Efficiency, a Metrics for an Optimal Molecular Mechanism of Action

Dr David SWINNEY
(IRND3, Mountain View, United States)

Drug Discovery by Programmed Self-Assembly

Prof. Nicolas WINSSINGER
(UNIVERSITY OF STRASBOURG, Geneva, Switzerland)

Bromodomains a New Class of Epigenetic Targets Ripe for Small Molecule Drug Discovery

Dr Jason WITHERINGTON
(GLAXOSMITHKLINE R&D, Stevenage, United Kingdom)

Validation of N-Myristoyltransferase as a Drug Target

Prof. Paul WYATT
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Accelerated C-H Activation Reactions: Enantioselectivity and Positional Selectivity

Confirmed Speakers

Prof Jin-Quan YU
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)

Selected Oral Communications

Small Molecule Inhibitors of the Neuropilin-1 VEGF-A Interaction

Dr Philip FALLON
(DOMAINEX, Saffron Walden, United Kingdom)

Halogen Bonding in Protein–ligand Interactions

Mr Leo HARDEGGER
(ETH ZURICH, Zürich, Switzerland)

The Chemical Biology Consortium- and Experimental Therapeutics Program

Dr Sanjay MALHOTRA
(NATIONAL CANCER INSTITUTE, Frederick, United States)

Adventures in Medicinal Chemistry and Knowledge Capture

Dr Alexander MAYWEG
(F. HOFFMANN-LA ROCHE LTD, BASEL, Switzerland)

Identification of Bisaryloxy Azetidine Urea Derivatives as Fatty Acid Amide Hydrolase Inhibitors

Dr Hans MEISSNER
(VERNALIS, Winnersh, United Kingdom)

Identification of Leads from the Tres Cantos Antimalarial Set: Cyclopropyl Carboxamides Show Good Oral Bioavailability and Efficacy In Malarial Animal Models

Mrs Maria Lourdes RUEDA-BENEDE
(GLAXOSMITHKLINE, Tres Cantos, Spain)

Highly Efficient Catalytic System for C-H Activation: A Novel and Practical Synthesis of Angiotensin II Receptor Blockers

Dr Masahiko SEKI
(MITSUBISHI TANABE PHARMA CORPORATION, Fukuoka, Japan)

The Grandisine Alkaloids as Selective μ -Opioid Receptor Agonists; When is a Natural Product not a Natural Product?

Prof. Richard TAYLOR
(UNIVERSITY OF YORK, York, United Kingdom)

Exploring the Rigid Mono- and Diamine Chemical Space

Dr Dmytro VOLOCHNYUK
(ENAMINE LTD., Kiev, Ukraine)

Lead identification of a new class of P2Y₁₂ inhibitors "From a low active and insoluble HTS hit to soluble and active lead compounds"

Mr Fredrik ZETTERBERG
(ASTRAZENECA, Gothenburg, Sweden)

The Chemistry of Targeting Protein-Protein Interactions: Thinking Outside of the Box

Dr Giovanna ZINZALLA
(CANCER RESEARCH UK - THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON, London, United Kingdom)